In humans, an enzyme called uridine diphosphate glycosyltransferase 8 (UGT8) is highly expressed in triple-negative breast cancer, and the osteoporosis drug zoledronic acid is a direct inhibitor of UGT8. A recent study by Professor Dong Chenfang from Zhejiang University School of Medicine showed that drugs for the treatment of osteoporosis are expected to be effective targeted drugs for the treatment of triple negative breast cancer. Recently, the research results were published in the internationally renowned journal "Journal of Experimental Medicine." About 1.2 million women worldwide suffer from breast cancer every year, and 10% to 20% of them are triple-negative breast cancer (ie, a special type of negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor) Breast cancer). Dong Chenfang introduced that the UGT8 enzyme has a very high degree of expression in triple-negative breast cancer, which is 4 to 8 times higher than normal cells or other subtypes of breast cancer, and is advantageous as a targeting molecule. Studies have shown that zoledronic acid can significantly inhibit the UGT8 enzyme activity in vitro, but also can significantly inhibit the formation of UGT8 product in tumor cells. Comparing UGT8-knocked tumor cells with zoledronic acid-treated tumor cells showed that both have a similar mechanism regulating cell metabolism and function. In both cell and animal models, zoledronic acid is effective in inhibiting the metastasis of triple-negative breast cancer cells, demonstrating better efficacy. These findings confirm that zoledronic acid is a direct inhibitor of UGT8 and has the potential to become a triple negative breast cancer targeting drug. Zoledronic acid is a safe marketed drug, and its relationship with cancer is being extensively studied, but there are no clinical trials for triple-negative breast cancer. Studies have shown that zoledronic acid combined with chemotherapy has a significant improvement over triple negative breast cancer compared to chemotherapy alone. Dong Chenfang said that these studies, combined with the team’s latest findings, all show that zoledronic acid is a huge possibility for targeted drugs. (correspondent Zeng Fuquan reporter Song Lisheng) 1000Hz High Frequency LiDAR System JRT High Frequency Range LiDAR Sensor is 2021 new product, that's a low-cost tof sensor but High frequency (up to 1000Hz). With 5cm high accuracy, the LiDAR Module can measure 80m.
Chengdu JRT Main Ranging Modules: Industrial Laser Distance Sensor, Laser Distance Meter Module, Tof LiDAR Sensor. lidar sensor,tof sensor,lidar system Chengdu JRT Meter Technology Co., Ltd , https://www.infrareddistancesensor.com
Why the 1000Hz High Frequency LiDAR System:
* Widely used in many industrial automation system, like, UAV, delivery van, anti-lock break system, construction automation,intelligent toy robots etc.
* Small size: 43*35*21mm, can be easily integrated
* Invisible laser design: the laser type is 905nm,Class I
* High Frequency: 1000hz/1khz
* Low power design
An osteoporosis drug or can cure breast cancer